Advaxis Concludes Patient Enrolment in Neoplasia Study

Advaxis has concluded patient recruitment in first low dose cohort in a Phase II trial.

Advaxis, a biotechnology company focused on cancer vaccines, has concluded enrolment of the first 40-subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for cervical intraepithelial neoplasia.

The randomised, single blind, placebo-controlled Phase II study is designed to evaluate the drug's safety and efficacy in up to three dose cohorts.

Advaxis chairman and CEO Thomas Moore said that the six-month follow-up evaluation for this first cohort will be completed by January 2012, and the low dose results are expected to be released in early 2012.